1. BUYtheWeak
2. nlanas2sk051p
3. MamisTrist
4. johnhoar
5. 7444s
1.johnhoar 02/08/2018
BMO Capital reiterates
2.johnhoar 03/10/2018
Praluent® (alirocumab) Injection Significantly Reduced Risk of Cardiovascular Events in High-Risk Patients, and was Associated with Lower Death Rate
3.BUYtheWeak 09/12/2017
@MamisTrist Yup, looking like it if you haven't already
4.johnhoar 01/30/2018
Great news - Company granted orphan drug designation by the FDA for its compound for the treatment of follicular lymphoma
5.MamisTrist 09/17/2018
Positive Phase 3 Results Presented for Dupixent® (dupilumab) Show Significant Improvement on Multiple Measures of Disease Severity in Adolescents with Moderate-to-Severe Atopic Dermatitis
6.BUYtheWeak 04/30/2018
FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma
7.BUYtheWeak 04/03/2018
Regeneron Pharmaceuticals and Sanofi announced that the European Medicines Agency has accepted for review th…
8.MamisTrist 09/12/2017
Time to buy?
9.johnhoar 04/03/2018
EMA to Review Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma
10.nlanas2sk051p 06/20/2018
Renewed M&A chatter
NEW since the last time you visited this board.
Currently a TOP 10 POST for this board.
Currently a TOP 5 RESEARCHER for this board.
Specific post has replies to it.
A Researcher you are currently FOLLOWING
Other Researchers rate this post HIGH
Other Researchers rate this post LOW